Zenas Biopharma, INC. (ZBIO) — 10-Q Filings
All 10-Q filings from Zenas Biopharma, INC.. Browse 3 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (3)
-
Zenas BioPharma's Losses Widen Amid Soaring R&D, Cash Drains
— Aug 12, 2025 Risk: high
Zenas BioPharma, Inc. (ZBIO) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $85.796 million, up from $65.777 milli -
Zenas BioPharma Files 10-Q, Details Xencor & Viridian Ties
— May 15, 2025 Risk: medium
Zenas BioPharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary business is in pharmaceutical preparations. Key relationships a -
Zenas BioPharma Q3 2024: Assets $81.2M, Liabilities $1.8M
— Nov 12, 2024 Risk: medium
Zenas BioPharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $81.24 million and total liabilities of $1.7
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX